Atara Biotherapeutics (NASDAQ:ATRA) CEO Anhco Nguyen Sells 5,062 Shares of Stock

Atara Biotherapeutics, Inc. (NASDAQ:ATRA) CEO Anhco Nguyen sold 5,062 shares of the business’s stock in a transaction that occurred on Monday, August 17th. The shares were sold at an average price of $8.08, for a total value of $40,900.96. Following the completion of the sale, the chief executive officer owned 132,775 shares of the company’s stock, valued at $1,072,822. The trade was a 3.67% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Atara Biotherapeutics Trading Down 4.7%

Shares of ATRA stock opened at $9.38 on Thursday. Atara Biotherapeutics, Inc. has a twelve month low of $3.92 and a twelve month high of $19.15. The stock has a fifty day simple moving average of $9.30 and a two-hundred day simple moving average of $7.54. The stock has a market capitalization of $94.18 million, a price-to-earnings ratio of -7.95 and a beta of 0.12.

Atara Biotherapeutics (NASDAQ:ATRA) last announced its quarterly earnings results on Wednesday, August 12th. The biotechnology company reported ($0.32) EPS for the quarter, meeting the consensus estimate of ($0.32). Atara Biotherapeutics had a negative return on equity of 79.12% and a negative net margin of 269.42%.The firm had revenue of $0.63 million for the quarter, compared to analyst estimates of $0.55 million. Research analysts predict that Atara Biotherapeutics, Inc. will post -0.16 EPS for the current fiscal year.

Hedge Funds Weigh In On Atara Biotherapeutics

A number of large investors have recently made changes to their positions in the business. Quadrature Capital Ltd lifted its holdings in shares of Atara Biotherapeutics by 22.8% during the 4th quarter. Quadrature Capital Ltd now owns 20,321 shares of the biotechnology company’s stock valued at $368,000 after purchasing an additional 3,779 shares during the last quarter. Bridgeway Capital Management LLC increased its stake in Atara Biotherapeutics by 133.5% during the 4th quarter. Bridgeway Capital Management LLC now owns 32,691 shares of the biotechnology company’s stock valued at $591,000 after purchasing an additional 18,691 shares in the last quarter. Marshall Wace LLP raised its stake in Atara Biotherapeutics by 28.4% in the 4th quarter. Marshall Wace LLP now owns 148,632 shares of the biotechnology company’s stock worth $2,689,000 after acquiring an additional 32,836 shares during the last quarter. Walleye Capital LLC purchased a new position in shares of Atara Biotherapeutics in the fourth quarter worth about $220,000. Finally, Renaissance Technologies LLC raised its position in Atara Biotherapeutics by 58.6% during the 4th quarter. Renaissance Technologies LLC now owns 30,040 shares of the biotechnology company’s stock worth $543,000 after buying an additional 11,104 shares during the last quarter. 70.90% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of equities analysts have recently issued reports on ATRA shares. Canaccord Genuity Group set a $13.00 price objective on shares of Atara Biotherapeutics and gave the company a “buy” rating in a research note on Friday, May 8th. Weiss Ratings raised Atara Biotherapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Tuesday, August 18th. Wall Street Zen raised Atara Biotherapeutics from a “sell” rating to a “hold” rating in a research report on Sunday, August 16th. Freedom Capital upgraded Atara Biotherapeutics from a “strong sell” rating to a “hold” rating in a research note on Monday, May 18th. Finally, TD Cowen upgraded shares of Atara Biotherapeutics to a “strong-buy” rating in a report on Monday. One investment analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, Atara Biotherapeutics presently has an average rating of “Moderate Buy” and an average price target of $9.50.

Atara Biotherapeutics Company Profile

Atara Biotherapeutics, Inc is a biotechnology company focused on the discovery, development and commercialization of novel T-cell immunotherapies to transform the treatment of cancer and autoimmune disease. Headquartered in South San Francisco, California, Atara leverages its proprietary off-the-shelf allogeneic Epstein-Barr virus (EBV)-directed T-cell platform to generate engineered cell therapies designed to target EBV-driven malignancies and immune-mediated disorders.

The company’s lead product candidate, tabelecleucel, is an off-the-shelf, EBV-specific T-cell therapy in clinical development for the treatment of EBV-positive post-transplant lymphoproliferative disease (PTLD) and other EBV-associated cancers.